TABRECTA® (capmatinib) tablets | Health Care Providers
Tabreta (capmatinib) Cancer Medication - Cancer Health
SAFETY, DOSING, AND ADMINISTRATION
PDF) Phase I dose‐escalation study of capmatinib ( INC 280) in Japanese patients with advanced solid tumors
Schematic representation of MET signaling blockade by capmatinib.... | Download Scientific Diagram
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer | JCO Precision Oncology
Capmatinib has a broad range of antiviral activity against human... | Download Scientific Diagram
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors - Clinical Therapeutics
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from a
Capmatinib + Nazartinib for EGFR-Mutant NSCLC - Journal of Oncology Navigation & Survivorship
Dosing & Administration | TABRECTA® (capmatinib) tablets
2 Synopsis
capmatinib
TABRECTA Cost | CAPMATINIB price | lung cancer treatment | FDA Approval | Online Available In India US UK AE SA BR RU CN
Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer
Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a two-drug cocktail in patients with MET-dysregulated advanced solid tumors: A phase I, multicenter, open-label, single-sequence drug-drug interaction study -
PDF) Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
These highlights do not include all the information needed to use TABRECTA safely and effectively. See full prescribing information for TABRECTA. TABRECTA® (capmatinib) tablets, for oral use Initial U.S. Approval: 2020
PDF) Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP)
Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts - Bang - 2020 - Cancer Science - Wiley Online Library
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced Non–Small-Cell Lung Cancer
Tabrecta (Capmatinib) Approved for Patients with Metastatic NSCLC and MET Exon 14 Skipping Mutation | Oncology Practice Management
